Draft:Pear Therapeutics
From Wikipedia, the free encyclopedia
Pear Therapeutics was a U.S.-based digital therapeutics company that developed software-based treatments for substance use disorders and other medical conditions.
 | Review waiting, please be patient.
This may take 2 months or more, since drafts are reviewed in no specific order. There are 4,259 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
The company focused on prescription digital therapeutics (PDTs), which are software applications designed to deliver clinically validated therapeutic interventions to patients.
History
Pear Therapeutics was founded in 2013 and was headquartered in Boston, Massachusetts.
The company became one of the first to receive clearance from the U.S. Food and Drug Administration (FDA) for a prescription digital therapeutic.
The company later pursued a public listing through a special purpose acquisition company (SPAC).[1]
In 2023, Pear Therapeutics filed for bankruptcy, and its assets were subsequently sold.[2]
Products
Pear Therapeutics developed software-based treatments intended to deliver behavioral therapy through digital platforms.
Key products included:
- reSET, a digital therapeutic for the treatment of substance use disorder
- reSET-O, a digital therapeutic for opioid use disorder
- 'Somryst, a digital therapeutic for chronic insomnia
These products were designed to deliver cognitive behavioral therapy (CBT) and other evidence-based interventions through structured digital programs.
Business model
Pear Therapeutics operated within the field of digital therapeutics, focusing on prescription-based software interventions integrated into healthcare systems.
The company partnered with healthcare providers, payers, and life sciences organizations.
Analyses of the company’s trajectory have highlighted challenges related to reimbursement, adoption, and market scalability.[3]
Scientific foundation
The company’s products were supported by clinical research, including randomized controlled trials evaluating their safety and effectiveness.
These studies reported improvements in treatment adherence and reductions in substance use when used alongside standard care.
Use
Pear Therapeutics’ products were prescribed by clinicians and used by patients as part of treatment programs for substance use disorders and other conditions.